Current Progress and Controversies in Prostate Cancer Management  被引量:3

Current Progress and Controversies in Prostate Cancer Management

在线阅读下载全文

作  者:De-Xin Dong Zhi-Gang Ji 

机构地区:[1]Department of Urology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing 100730, China

出  处:《Chinese Medical Journal》2017年第24期2991-2995,共5页中华医学杂志(英文版)

摘  要:Objective:The optimal management strategy for prostate cancer (PCa) remains controversial.We performed a systemic review of current progress and controversies regarding the diagnosis and treatment of PCa.Data Sources:We searched PubMed for recently published articles up to July 2017 using the following key words:"prostate cancer," "progress," "controversy," "immunotherapy," and "prevention." Study Selection:Articles were obtained and reviewed to provide a systematic review of the current progress and controversies regarding PCa management.Results:The value of serum prostate-specific antigen (PSA) screening remains controversial,but PSA screening is recommended to facilitate the early diagnosis of PCa in high-risk groups.Prostate biopsy via the transrectal or perineal approach has both advantages and disadvantages.There was a significant correlation between testosterone levels and PCa prognosis.The current research is focused on the mechanisms responsible for PCa.Active surveillance has been proposed as a management strategy for low-risk,localized PCa,but there is an urgent need for further clinical studies to establish the criteria for recommending this approach.The main complications of radical resection for PCa are urinary incontinence and erectile dysfunction,though three-dimensional laparoscopic and robot-assisted laparoscopic techniques have obvious advantages over radical surgery.Radiotherapy is also a therapeutic option for PCa,while immunotherapies may alter the prostate tumor microenvironment.Ongoing studies aim to provide guidance on effective sequential and combination strategies.Prevention remains an important strategy for reducing PCa morbidity and mortality.Conclusions:The diagnosis,treatment,and prevention of PCa are complex issues,worthy of intensive study.Further studies are needed to improve the management of PCa.Objective:The optimal management strategy for prostate cancer (PCa) remains controversial.We performed a systemic review of current progress and controversies regarding the diagnosis and treatment of PCa.Data Sources:We searched PubMed for recently published articles up to July 2017 using the following key words:"prostate cancer," "progress," "controversy," "immunotherapy," and "prevention." Study Selection:Articles were obtained and reviewed to provide a systematic review of the current progress and controversies regarding PCa management.Results:The value of serum prostate-specific antigen (PSA) screening remains controversial,but PSA screening is recommended to facilitate the early diagnosis of PCa in high-risk groups.Prostate biopsy via the transrectal or perineal approach has both advantages and disadvantages.There was a significant correlation between testosterone levels and PCa prognosis.The current research is focused on the mechanisms responsible for PCa.Active surveillance has been proposed as a management strategy for low-risk,localized PCa,but there is an urgent need for further clinical studies to establish the criteria for recommending this approach.The main complications of radical resection for PCa are urinary incontinence and erectile dysfunction,though three-dimensional laparoscopic and robot-assisted laparoscopic techniques have obvious advantages over radical surgery.Radiotherapy is also a therapeutic option for PCa,while immunotherapies may alter the prostate tumor microenvironment.Ongoing studies aim to provide guidance on effective sequential and combination strategies.Prevention remains an important strategy for reducing PCa morbidity and mortality.Conclusions:The diagnosis,treatment,and prevention of PCa are complex issues,worthy of intensive study.Further studies are needed to improve the management of PCa.

关 键 词:Active Surveillance ADVANCE lmmunotherapy PREVENTION Prostate Cancer 

分 类 号:R0[医药卫生]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象